CLDX
Price
$25.65
Change
-$0.04 (-0.16%)
Updated
Jan 16 closing price
Capitalization
1.7B
43 days until earnings call
Intraday BUY SELL Signals
DNTH
Price
$44.10
Change
+$0.10 (+0.23%)
Updated
Jan 16 closing price
Capitalization
1.89B
Intraday BUY SELL Signals
Interact to see
Advertisement

CLDX vs DNTH

Header iconCLDX vs DNTH Comparison
Open Charts CLDX vs DNTHBanner chart's image
Celldex Therapeutics
Price$25.65
Change-$0.04 (-0.16%)
Volume$675.54K
Capitalization1.7B
Dianthus Therapeutics
Price$44.10
Change+$0.10 (+0.23%)
Volume$638.64K
Capitalization1.89B
CLDX vs DNTH Comparison Chart in %
View a ticker or compare two or three
VS
CLDX vs. DNTH commentary
Jan 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and DNTH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 18, 2026
Stock price -- (CLDX: $25.65 vs. DNTH: $44.10)
Brand notoriety: CLDX and DNTH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 88% vs. DNTH: 82%
Market capitalization -- CLDX: $1.7B vs. DNTH: $1.89B
CLDX [@Biotechnology] is valued at $1.7B. DNTH’s [@Biotechnology] market capitalization is $1.89B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileDNTH’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • DNTH’s FA Score: 1 green, 4 red.
According to our system of comparison, DNTH is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 3 TA indicator(s) are bullish while DNTH’s TA Score has 4 bullish TA indicator(s).

  • CLDX’s TA Score: 3 bullish, 5 bearish.
  • DNTH’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both CLDX and DNTH are a bad buy in the short-term.

Price Growth

CLDX (@Biotechnology) experienced а -6.32% price change this week, while DNTH (@Biotechnology) price change was +15.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was +4.14%, and the average quarterly price growth was +42.40%.

Reported Earning Dates

CLDX is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($1.89B) has a higher market cap than CLDX($1.7B). DNTH YTD gains are higher at: 7.013 vs. CLDX (-5.560). DNTH has higher annual earnings (EBITDA): -139.9M vs. CLDX (-252.86M). CLDX has more cash in the bank: 583M vs. DNTH (403M). DNTH has less debt than CLDX: DNTH (1.29M) vs CLDX (2.62M). DNTH has higher revenues than CLDX: DNTH (3.08M) vs CLDX (2.6M).
CLDXDNTHCLDX / DNTH
Capitalization1.7B1.89B90%
EBITDA-252.86M-139.9M181%
Gain YTD-5.5607.013-79%
P/E RatioN/A3.24-
Revenue2.6M3.08M84%
Total Cash583M403M145%
Total Debt2.62M1.29M204%
FUNDAMENTALS RATINGS
CLDX vs DNTH: Fundamental Ratings
CLDX
DNTH
OUTLOOK RATING
1..100
1744
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
8421
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
5437
P/E GROWTH RATING
1..100
10066
SEASONALITY SCORE
1..100
4185

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (69) in the Biotechnology industry is in the same range as DNTH (69) in the null industry. This means that CLDX’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's Profit vs Risk Rating (21) in the null industry is somewhat better than the same rating for CLDX (84) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than CLDX’s over the last 12 months.

DNTH's SMR Rating (96) in the null industry is in the same range as CLDX (96) in the Biotechnology industry. This means that DNTH’s stock grew similarly to CLDX’s over the last 12 months.

DNTH's Price Growth Rating (37) in the null industry is in the same range as CLDX (54) in the Biotechnology industry. This means that DNTH’s stock grew similarly to CLDX’s over the last 12 months.

DNTH's P/E Growth Rating (66) in the null industry is somewhat better than the same rating for CLDX (100) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXDNTH
RSI
ODDS (%)
Bearish Trend 7 days ago
79%
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 14 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CLDX
Daily Signal:
Gain/Loss:
DNTH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
COICX18.27N/A
N/A
Calvert International Opportunities C
PCMSX16.30-0.02
-0.12%
Principal MidCap Value I R6
HBLIX14.81-0.02
-0.13%
Hartford Balanced Income I
REBYX27.18-0.09
-0.33%
Russell Inv US Small Cap Equity Y
NBRAX27.28-0.13
-0.47%
Neuberger M/C Intrinsic Val A

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KURA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-0.16%
KURA - CLDX
55%
Loosely correlated
-5.05%
VIR - CLDX
55%
Loosely correlated
-2.26%
XNCR - CLDX
54%
Loosely correlated
-3.18%
NUVL - CLDX
52%
Loosely correlated
-1.79%
VRDN - CLDX
52%
Loosely correlated
+0.70%
More

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with VRDN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+0.23%
VRDN - DNTH
47%
Loosely correlated
+0.70%
XNCR - DNTH
44%
Loosely correlated
-3.18%
RVMD - DNTH
44%
Loosely correlated
-2.43%
CLDX - DNTH
44%
Loosely correlated
-0.16%
ORKA - DNTH
43%
Loosely correlated
+2.77%
More